-
Rosenior plots long Chelsea stay as Arsenal loom
-
Zuckerberg names banker, ex-Trump advisor as Meta president
-
Reza Pahlavi: Iran's ex-crown prince dreaming of homecoming
-
Venezuela releases more political prisoners
-
Kenya's NY marathon champ Albert Korir gets drug suspension
-
US prosecutors open probe of Fed chief, escalating Trump-Powell clash
-
Russian captain in fiery North Sea crash faces UK trial
-
Carrick is frontrunner for interim Man Utd job: reports
-
Iran government stages mass rallies as alarm grows over protest toll
-
Variawa leads South African charge over Dakar dunes
-
Swiss inferno bar owner detained for three months
-
Heathrow airport sees record high annual passenger numbers
-
Georgia jails ex-PM for five years amid ruling party oustings
-
Kyiv buries medic killed in Russian drone strike
-
Israel revokes French researcher's travel permit
-
India and Germany seek to boost defence industry ties
-
French coach and football pundit Rolland Courbis dies at 72
-
UK regulator opens probe into X over sexualised AI imagery
-
AFCON organisers investigate incidents after Algeria-Nigeria clash
-
US Fed chief warns of 'intimidation' after criminal subpoenas
-
Iran says 'prepared for war' as alarm grows over protest toll
-
India and Germany eye defence industry boost to ties
-
'I know the pain': ex-refugee takes over as UNHCR chief
-
US prosecutors open criminal probe into Federal Reserve
-
Rohingya 'targeted for destruction' by Myanmar, ICJ hears
-
'Genius' chimpanzee Ai dies in Japan at 49
-
Trump says US will take Greenland 'one way or the other'
-
Myanmar pro-military party claims Suu Kyi's seat in junta-run poll
-
Fed chair Powell says targeted by federal probe
-
Trailblazing Milos Raonic retires from tennis
-
Australia recalls parliament early to pass hate speech, gun laws
-
'One Battle After Another,' 'Hamnet' triumph at Golden Globes
-
Japan aims to dig deep-sea rare earths to reduce China dependence
-
Top UN court to hear Rohingya genocide case against Myanmar
-
US sends more agents to Minneapolis despite furor over woman's killing
-
Trump says Iran 'want to negotiate' after reports of hundreds killed in protests
-
Bangladesh's powerful Islamists prepare for elections
-
NBA-best Thunder beat the Heat as T-Wolves edge Spurs
-
Ukraine's Kostyuk defends 'conscious choice' to speak out about war
-
Trump says working well with Venezuela's new leaders, open to meeting
-
Asian equities edge up, dollar slides as US Fed Reserve subpoenaed
-
Hong Kong court hears sentencing arguments for Jimmy Lai
-
Powell says Federal Reserve subpoenaed by US Justice Department
-
Chalamet, 'One Battle' among winners at Golden Globes
-
Turning point? Canada's tumultuous relationship with China
-
Eagles stunned by depleted 49ers, Allen leads Bills fightback
-
Globes red carpet: chic black, naked dresses and a bit of politics
-
Maduro's fall raises Venezuelans' hopes for economic bounty
-
Golden Globes kick off with 'One Battle' among favorites
-
Australian Open 'underdog' Medvedev says he will be hard to beat
Cardiff Lexington Announces 1-for-3 Reverse Stock Split
LEXINGTON, KY / ACCESS Newswire / January 12, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) ("Cardiff" or the "Company"), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced a 1-for-3 reverse stock split of its issued and outstanding common stock, par value $0.001 per share (the "Reverse Stock Split"), which became effective as of 12:01 a.m. Eastern Time on January 12, 2026. Each 3 shares of the issued and outstanding Common Stock shall be reclassified and combined into 1 share of Common Stock (the "Reverse Split"). No fractional shares shall be issued in connection with the Reverse Split. Any fractional share that would otherwise be issued shall be rounded up to the next whole share. The Company's common stock continues to trade on The OTCQB Venture Market under the symbol "CDIX" and is expected to begin trading on a split-adjusted basis on the OTCQB Venture Market at the commencement of trading today. Following the Reverse Stock Split, the Company's ticker symbol will be CDIXD for 20 trading days including the effective date.
The primary purpose of the Reverse Stock Split is to support compliance with the minimum bid price requirement for the listing of the Company's common stock on the Nasdaq Capital Market and was approved by the Company's Board of Directors and stockholders and implemented pursuant to the authority granted under Nevada Revised Statutes and the Company's Articles of Incorporation.
Alex Cunningham, President and CEO of Cardiff Lexington, commented, "This reverse stock split supports our planned uplisting to the Nasdaq Capital Market as we continue to strengthen our capital markets profile and enhance our visibility among institutional investors."
Upon effectiveness of the Reverse Stock Split:
Each three (3) shares of issued and outstanding common stock were automatically combined into one (1) share of common stock.
The par value of the common stock was unchanged.
No fractional shares were issued; any fractional share resulting from the Reverse Stock Split was rounded up to the nearest whole share, consistent with Nevada law and the Company's governing documents.
The Reverse Stock Split did not change any stockholder's proportional ownership interest, except for minor differences resulting from the rounding of fractional shares. The Company's post-Reverse Stock Split common stock CUSIP number will be 14146R700.
About Cardiff Lexington Corporation
Cardiff Lexington Corporation (OTCQB: CDIX) is a healthcare holding company focused on acquiring, operating, and optimizing high-margin medical practices in Orthopedics, Spine Care, and Pain Management. The Company leverages deep sector experience, disciplined capital deployment, and lean operating structures to build a profitable, scalable, and resilient growth platform in one of the strongest segments of U.S. healthcare.
Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the intended effect of the Reverse Stock Split and the Company's ability to maintain compliance with OTCQB and Nasdaq Capital Market listing requirements. These statements are based on current expectations, estimates, and projections and involve risks and uncertainties, including market conditions and investor response, which could cause actual results to differ materially. Cardiff Lexington Corporation undertakes no obligation to update or revise forward-looking statements except as required by law.
Investor Contact
Cardiff Lexington Investor Relations
[email protected]
(800) 375-2349
Or
IMS Investor Relations
[email protected]
(203) 972-9200
SOURCE: Cardiff Lexington Corporation
View the original press release on ACCESS Newswire
P.Costa--AMWN